Consultants divided on value of EU joint-bone health claim guidance
date:May 30, 2012
tolerated as supportive evidence,Alexander added.

Although lots of new research has clearly elucidated the molecular and cellular mechanisms leading to joint health pathology, especially in the case of early stages of osteoarthritis, EFSAs latest opinion on glucosamine effects submitted by Merck reveals the very conservative attitude still in existence towards joint health research.

Unfortunately, this will lead to devastating changes in the market place, opening all doors to dubious products
4/7 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/02 09:19